Johnson & Johnson (JNJ) Deutsche Bank 2026 Healthcare Summit summary

Strategic business overview

• Focus remains on higher growth markets with strong positions in oncology, immunology, neuroscience, surgery, vision, and cardiovascular.

• Portfolio balance between pharmaceuticals and med tech is not fixed; each business must compete effectively in its market.

• Diversification provides flexibility to invest in R&D and manage loss of exclusivity events.

• Ongoing portfolio review ensures alignment with innovation and patient impact.

• Recent and ongoing separations from consumer and orthopedics aim to focus on higher growth, higher margin areas.

Growth outlook and financial performance

• Revenue grew 6.6% in Q2, with a raised outlook for 2026 and a long-term growth target of 5% to 7%.

• Clear line of sight to double-digit growth by the end of the decade, with normalization for extra sales weeks in 2026.

• Portfolio is largely de-risked, with new launches and under-penetrated markets supporting future growth.

• Cash conversion targeted at $21 billion for the year, expected to grow substantially.

• Margin improvement anticipated through operational efficiencies and technology adoption.

Med tech segment developments

• Strong presence in surgery, vision, and cardiovascular, with recent approvals like OTTAVA robotics platform.

• VARIPULSE and VARIPULSE Pro gaining traction in pulsed field ablation, with plans for U.S. launch.

• Shockwave acquisition positions the company as a leader in circulatory restoration despite new competition.

• Med tech margins expected to improve, though not to pharmaceutical levels; surgery and vision are margin leaders.

• Abiomed business faces short-term headwinds but is expected to return to double-digit growth after new study results.